Model-Assisted Bayesian Designs for Dose Finding and Optimization (Chapman & Hall/CRC Biostatistics Series) 1st Edition
₨ 500 – ₨ 900Price range: ₨ 500 through ₨ 900
Model-Assisted Bayesian Designs for Dose Finding and Optimization (Chapman & Hall/CRC Biostatistics Series) 1st Edition
Bayesian adaptive designs provide a critical approach to improve the efficiency and success of drug development that has been embraced by the US Food and Drug Administration (FDA). This is particularly important for early phase trials as they form the basis for the development and success of subsequent phase II and III trials.
The objective of this book is to describe the state-of-the-art model-assisted designs to facilitate and accelerate the use of novel adaptive designs for early phase clinical trials. Model-assisted designs possess avant-garde features where superiority meets simplicity. Model-assisted designs enjoy exceptional performance comparable to more complicated model-based adaptive designs, yet their decision rules often can be pre-tabulated and included in the protocol—making implementation as simple as conventional algorithm-based designs. An example is the Bayesian optimal interval (BOIN) design, the first dose-finding design to receive the fit-for-purpose designation from the FDA. This designation underscores the regulatory agency’s support of the use of the novel adaptive design to improve drug development.
This book is available at Books Hub Pk. Order now and get home delivery all over Pakistan within 3 Working days.
Model-Assisted Bayesian Designs for Dose Finding and Optimization (Chapman & Hall/CRC Biostatistics Series) 1st Edition
Bayesian adaptive designs provide a critical approach to improve the efficiency and success of drug development that has been embraced by the US Food and Drug Administration (FDA). This is particularly important for early phase trials as they form the basis for the development and success of subsequent phase II and III trials.
The objective of this book is to describe the state-of-the-art model-assisted designs to facilitate and accelerate the use of novel adaptive designs for early phase clinical trials. Model-assisted designs possess avant-garde features where superiority meets simplicity. Model-assisted designs enjoy exceptional performance comparable to more complicated model-based adaptive designs, yet their decision rules often can be pre-tabulated and included in the protocol—making implementation as simple as conventional algorithm-based designs. An example is the Bayesian optimal interval (BOIN) design, the first dose-finding design to receive the fit-for-purpose designation from the FDA. This designation underscores the regulatory agency’s support of the use of the novel adaptive design to improve drug development.
This book is available at Books Hub Pk. Order now and get home delivery all over Pakistan within 3 Working days.
| Quality | Black & white, Colour Matt Finish |
|---|
Only logged in customers who have purchased this product may leave a review.
Related products
Advanced Statistics in Regulatory Critical Clinical Initiatives (Chapman & Hall/CRC Biostatistics Series) 1st Edition
₨ 800 – ₨ 1,200Price range: ₨ 800 through ₨ 1,200
Bayesian Thinking in Biostatistics (Chapman & Hall/CRC Texts in Statistical Science) 1st Edition
₨ 1,500 – ₨ 2,280Price range: ₨ 1,500 through ₨ 2,280
Data Science, AI, and Machine Learning in Drug Development (Chapman & Hall/CRC Biostatistics Series) 1st Edition
₨ 800 – ₨ 1,220Price range: ₨ 800 through ₨ 1,220
Modern Biostatistical Methods for Evidence-Based Global Health Research (Emerging Topics in Statistics and Biostatistics) 1st ed.
₨ 1,260 – ₨ 1,910Price range: ₨ 1,260 through ₨ 1,910
Recent Advances on Sampling Methods and Educational Statistics: In Honor of S. Lynne Stokes (Emerging Topics in Statistics and Biostatistics) 1st ed.
₨ 760 – ₨ 1,160Price range: ₨ 760 through ₨ 1,160SEQs and MCQs Solved Past Papers Biostatistics and Research Method
SEQs and MCQs Solved Past Papers Biostatistics and Research Method and EBP

Reviews
There are no reviews yet.